Microsoft word - cv-dmm jun2013_for website.doc
DAVID M. MOTTOLA, PHD
Pharmaceutical/Biotech Industry Experience
• 21+ years R&D experience – in start-up, mid-size and large pharma settings
• Cofounded new pharmaceutical company and led start-up activities
• Led key global drug development strategies and activities: nonclinical program, IND submission,
Phase 1 Clinical Pharmacology program, Phase 2 studies, FDA/EMA regulatory strategy and
discussions, CMC support, Phase 3 multi-national pivotal studies, NDA submission, post
approval commitments, Orphan Drug Designation filings, business development and due
• Direct management and oversight of many R&D functional areas: Clinical Operations, Clinical
Sciences, Project Management, Statistics and Data Management, Regulatory Affairs and
Compliance, Pharmaceutical Development, etc.
• Therapeutic area experience: cardiovascular, cardiopulmonary, hepatology, ophthalmology
• 5 NDA approvals, 2 Orphan Drug Designation approvals
, University of North Carolina, Chapel Hill, NC
, State University of New York, Binghamton, NY
ACRIS Pharmaceuticals, LLC
- Cofounder, President & Chief Operating Officer
United Therapeutics Corp
.& Lung (Rx), LLC
(subsidiary of United Therapeutics)
Research Triangle Park, North Carolina, and Silver Spring, Maryland
Held progressive leadership roles at United Therapeutics starting in 1999 and in 2010 was asked to lead Research and Development activities for Lung (Rx), LLC, a wholly owned subsidiary of the parent company, United Therapeutics.
- Executive Vice President, Research and Clinical Development
(Lung Rx, LLC)
- Senior Vice President, Clinical Operations, Clinical Quality and Standards and Preclinical Sciences
- Senior Vice President, Clinical Operations and Preclinical Sciences
- Senior Vice President, Product Development
- Vice President, Product Development
Bausch & Lomb Pharmaceuticals Inc
- Senior Manager, Clinical and Scientific Affairs
Burroughs Wellcome Co./ Glaxo Wellcome Inc
- Principal Clinical Research Scientist
- Senior Clinical Research Scientist
Led company start-up activities including business strategy, IP evaluations, deal structure
oversight, fund raising, company infrastructure set-up and management
Direct responsibility for R&D department activities (strategic vision, leadership, goal setting,
budget projections and management, resource allocation, project priorities, personnel development, department growth, and SOPs/policies, etc.)
Managed and directed activities across various R&D functional departments (clinical,
nonclinical [pharmacology and toxicology], pharmaceutical development, analytical sciences, statistics and data management, project management, regulatory and compliance, etc.)
Led and supported multiple global/multi-national proprietary drug development programs
(Phases 1 - 3) covering various therapeutic areas
Foster key opinion leader (KOL) relationships and KOL management
Directed and supported Phase 3 study Oversight Committees (Steering Committee, DSMC,
Actively contributed to regulatory submissions for multiple New Drug Applications (NDA),
European Marketing Authorization Application (MAA), Investigational New Drug (IND) applications and equivalent applications in Europe and Asia, Orphan Drug Designation applications, and generic ANDA submissions and various responses to queries from regulatory authorities
Oversight of all functional aspects of development programs (e.g., clinical, non-clinical,
chemistry, manufacturing, controls (CMC), overall budgets, international project team, etc.)
Directed/authored project specific documents (e.g., clinical development plans, protocols, study
reports, etc.) and project-related publications (manuscripts and abstracts)
Presented project/company information to regulatory authorities, project advisory boards,
Worked closely with other company departments (e.g., compliance, legal, licensing, marketing,
sales/commercial, etc.) to support development, launch and commercialization of new products
Oversight of international department personnel selection (hiring/firing) and strategic growth
Serve on Senior Management Council to discuss development programs, sales and marketing
initiatives, budget issues and growth strategies
Evaluation of strategic business opportunities, related due diligence, licensing agreements
Served on Joint Development Committees for partnered projects
1. Gotzkowsky SK, Kumar P, Mottola D and Laliberte, K. Lack of a Pharmacokinetic Interaction
Between Treprostinil Diolamine and Sildenafil in Healthy Adult Volunteers. J. Clin. Pharmacol.
2. Whittle BJ, Silverstein AM, Mottola DM, and Clapp LH. Binding and activity of the prostacyclin
receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a
potent DP1 and EP2 agonist. Biochem. Pharmacol. 84:68-75, 2012
3. Gotzkowsky SK, Dingemanse J, Lai A, Mottola D and Laliberte, K Lack of pharmacokinetic
interaction between oral treprostinil and Bosentan in healthy adult volunteers. J. Clin. Pharmacol.
4. Sandifer BL, Brigham KL, Lawrence EC, Mottola D, Cuppels C and Parker RE. Potent effects of
aerosol compared with intravenous treprostinil on the pulmonary circulation. J. Appl. Phys.
5. Mottola, DM, Lawler CP, Jones SR, Einhorn L, Booth RG, Wightman M, Nichols DE and
Mailman RB. Functional selectivity of dopamine D2 receptors. I. Novel postsynaptic functional
selectivity of dihydrexidine and its analogs in the rat central nervous system. J. Pharmacol. Exp.
6. Mottola, DM, S Laiter, VJ Watts, A. Tropsha, SD Wyrick, DE Nichols, and RB Mailman.
Conformational Analysis of D1 Dopamine Receptor Agonists: Pharmacophore Assessment and
Receptor Mapping. J. Med. Chem. 39:285-296, 1996.
7. Brewster, WK, DE Nichols,VJ Watts, RM Riggs, DM Mottola, and RB Mailman. Evaluation of
Cis and Trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as
Structurally Rigid, Selective D1 Dopamine Receptor Ligands. J. Med. Chem. 38:318-327, 1995.
8. Knoerzer, TA, DE Nichols, WK Brewster, VJ Watts, DM Mottola, and RB Mailman.
Dopaminergic Benzo[a]phenanthridines: Resolution and Pharmacological Evaluation of the
Enantiomers of Dihydrexidine, the Full Efficacy D1 Dopamine Receptor Agonist. J. Med. Chem.
9. Mottola, DM, WK Brewster, LL Cook, DE Nichols and RB Mailman. Dihydrexidine, a Novel
Full Efficacy D1 Dopamine Receptor Agonist. J. Pharmacol. Exp. Ther. 262: 383-393 1992.
10. Brewster, WK, DE Nichols, RM Riggs, DM Mottola, TW Lovenberg, MH Lewis and RB
Mailman. Trans-10,11-Dihydroxy-5,6,6a,7,8,12b-Hexahydrobenzo[a]phenanthridine: A highly
potent selective dopamine D1 full agonist. J. Med. Chem. 33: 1756-1764 1990.
11. Lovenberg, TW, WK Brewster, DM Mottola, RC Lee, RM Riggs, DE Nichols, MH Lewis and
RB Mailman. Dihydrexidine, a novel selective high potency full D1 dopamine receptor agonist.
Phares K and D Mottola, United Therapeutics Corp. US Patent No.: 7,384,978; 7,417,070;
7,544,713; 8,232,316; 8,252,839; 8,410,169 (Family ID 34079029) “Compounds and methods for
delivering prostacyclin analogs” - Issued 2008-2013.
Mottola, DM Nonanol. In Browning's Toxicology and Metabolism of Industrial Solvents
, Vol. IV:
Alcohols and Esters. RG Thurman and FC Kauffman eds. Elsevier Biomedical Press. 1992.
1. Armstrong D, Wargin W, Mottola DM and Sullivan EJ. A Phase 1, single-center, single-dose,
open-label, randomized crossover, comparative bioavailability and food effect study to compare
BPS-314d-MR 15 µg and 60 µg tablet formulations to the existing BPS-MR 60 µg tablet
formulation in healthy volunteers. American Thoracic Society Meeting, 2012.
2. Tapson V, Torres F, Kermeen F, Keogh A, Allen R, Franz R, Badesch D, Frost A, Shapiro S,
Sigman, Grover R, Laliberte K, Mottola D, Galie N, and Simmoneau G. Results of FREEDOM-
C: A pivotal study of oral treprostinil used adjunctively with an ERA and/or PDE5-inhibitor for
the treatment of PAH. American Thoracic Society Meeting, 2009
3. White R, Allen R, Torres F, Jeres C, Pulido T, Carroll J, Yehle D, Laliberte K, Mottola D, Galie
N, Simmoneau G, and Tapson V. Sustained Plasma Concentrations of Treprostinil following
Chronic Dosing in Patients with Pulmonary Arterial Hypertension (PAH). American Thoracic
4. Rollins K, Laliberte K, Gotzkowsky, K, Wade M and Mottola D Overview of the drug-drug
interactions potential with treprostinil. American Thoracic Society Meeting, 2009
5. White R, Allen R, Yehle D, Laliberte K, Mottola D, Galie N, Simmoneau G, Tapson V. Oral
Treprostinil Diethanolamine Provides Sustained Therapeutic Plasma Concentrations Over a Wide
Range of Doses in Patients with Pulmonary Arterial Hypertension. American Thoracic Society
6. Berman SS, RC Quick, C Johnson, D Strootman, K Rollins, D Mottola, McLafferty. Efficacy of
an oral prostacyclin analog (treprostinil diethanolamine) in patients with advanced lower
extremity peripheral arterial disease and ischemic rest pain. Society for Clinical Vascular
7. Laliberte K, Goetz B, Phares K, Mottola D. Sustained Treprostinil Plasma Concentrations
Following Administration of UT-15C (Treprostinil Diethanolamine) Sustained Release Tablets
in Healthy Volunteers. American Thoracic Society Meeting, 2007
8. Gotzkowsky K, Dingemanse J, Laliberte K, Goetz B, Mottola D. Lack of a Pharmacokinetic
Drug Interaction Following Co-Administration of UT-15C (treprostinil diethanolamine) SR and
Tracleer® (bosentan) in Healthy Volunteers. American Thoracic Society Meeting, 2007
9. Gotzkowsky K, Laliberte K, Goetz B, Mottola D. Lack of a Pharmacokinetic Drug Interaction
Following Co-Administration of UT-15C (treprostinil diethanolamine) SR and Revatio™
(sildenafil citrate) in Healthy Volunteers. American Thoracic Society Meeting, 2007
10. Staszewski J, K Phares and D Mottola. Development of an oral prostacyclin analog (treprostinil
diethanolamine) for the treatment of pulmonary arterial hypertension. American Chemical
11. Mottola D, Laliberte K, Phares K, Davis G, Flinchbaugh R, Spezzi A, Warrington S.
Pharmacokinetics and safety of treprostinil diethanolamine (UT-15C), a novel salt of treprostinil
for oral delivery. American Thoracic Society Meeting, 2005
12. Gibbs JS, CP Arneson, D Mottola for treprostinil study group. Chronic infusion of treprostinil is
safe, and appears to prolong survival over a three-year period in patients with pulmonary arterial
hypertension. American Heart Association Meeting, Abstr. 2002.
13. Watson, D, J Donaldson, R Grover, D Mottola, K Guntupalli and J-L Vincent for the Wellcome
International Septic Shock Study Group. The cardiopulmonary effects of 546C88 in human
septic shock. Proceedings of the European Congress of Intensive Care Medicine, Abstr.
14. Watts, VJ, DM Mottola, O Civelli, RA Johnson, DE Nichols and RB Mailman. Dihydrexidine
binds differently to human clonal and rat striatal D1 receptors. Soc. Neurosci. Abstr. 18:124.15
15. Mooney, DH, DM Mottola, SB Southerland, TA Knoerzer, DE Nichols and RB Mailman.
Substitutions on the pendent phenyl ring of dihydrexidine alter D1:D2 selectivity. Soc. Neurosci.
16. Mailman, RB, A Tropsha, DM Mottola, SD Wyrick and DE Nichols. Molecular modeling of D1
dopamine receptors: Pharmacophore assessment and Receptor Mapping. International
17. Mottola, DM, LL Cook, SR Jones, RG Booth, DE Nichols and RB Mailman. Dihydrexidine, a
selective dopamine receptor agonist that may discriminate postsynaptic D2 receptors. Soc.
18. Cook, LL, DM Mottola, JM Petitto, MH Lewis and RB Mailman. Functional interactions of
striatal D1 and D2 dopamine receptors: effects of tissue preparation and lesions. Soc. Neurosci.
19. Mottola, DM, WK Brewster, DE Nichols and RB Mailman. Dihydrexidine, a novel agonist to
study the pharmacology and structural requirements of D1 dopamine receptors. Soc. Neurosci.
20. Cook, LL, DM Mottola, WK Brewster, DE Nichols MH Lewis and RB Mailman. Dihydrexidine
is potent and fully efficacious D1 dopamine receptor agonist in vivo and in vitro. Soc. Neurosci.
21. Mottola, DM, K Brewster, J Bennet, TW Lovenberg, CP Lawler, MH Lewis, S Southerland, D
Nichols and RB Mailman. In vivo and in vitro actions of DHBP, a unique agonist for both D1 and
22. Lovenberg, TW, K Brewster, DM Mottola, J Bennet, D Nichols and RB Mailman. A Novel
Ligand Differentiating Multiple D1 Dopamine Receptors. FASEB J. 3:A749 1989.
The world has changed in the past 10 years. Companies can go from obscurity to an estimated $100 billion market cap(Facebook) or from zero to $1 billion in revenue very quickly (Groupon did it in two years), or from near collapse in the late‘90s to become one of the world’s most valuable companies (Apple). To succeed today, companies need to embrace change, inways that include learning to mark
9. Supervisor of completed PhD-studies and Postdoctoral works 10. Organisation of Symposia and Workshops 11. Publications 11.1 Publications (peer-reviewed) Switzerland E-mail: [email protected] Phone: +41 61 321 13 15 Cellular: +76 549 75 15 1. Personal information Date of Birth: 27.02.1971 Place of Birth: Ravensburg/Germany Nationality: German Marital status: Civil partnership